BioSpace News Archive

Albany NY, United States: Copper has gathered massive traction in medical tubing applications on account of their array of promising physical properties particularly durability and flexibility.

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that an abstract reporting preliminary data from the two Phase I trials assessing TG4050, its individualized neoantigen cancer vaccine, has been selected for a poster presentation at the American Society of Clinical Oncology annual meeting.

Zymeworks Inc., a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, announced that management will participate in an upcoming investor conference:

Renowned Scientists, Researchers, and Clinicians Will Convene at the 8th Annual Event June 10-11 in Vienna, Austria.

Invitae (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in the following investor conferences.

FDA granted IND clearance for ITIL-306, Instil’s first genetically-engineered CoStAR-TIL therapy for the treatment of NSCLC, RCC, and ovarian cancer Instil to present in vivo data with CoStAR T cells demonstrating enhanced expansion, persistence, and tumor control at the 2022 ASCO Annual Meeting.

Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today reported that it has commenced sales of its CompuFlo ® Epidural instrument disposables at a leading veterinary and academic institution following a successful research study and evaluation.

OnQuality Pharmaceuticals today announced it will have two abstracts published in the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings, a Journal of Clinical Oncology supplement, on June 3, 2022.

INOVIO’s DNA medicines immunotherapy in combination with Libtayo ® elicits vaccine-associated immune responses when administered with RT/TMZ to newly diagnosed GBM patients.

Bolt Biotherapeutics, Inc. today announced that it will be presenting a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held at McCormick Place in Chicago and virtually from June 3-7, 2022.